NSEOutcome of Board Meeting6h ago · 23 Jul 2026, 01:17 pm

Outcome of Board Meeting

Solara Active Pharma Sciences Limited · SOLARA

✦ AI SummaryResults

Solara Active Pharma Sciences Limited has informed the exchange about the outcome of its board meeting held on July 23, 2026, where the board considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report for the said period.

Attachments (1)

📄

SOLARA_23072026131622_SE_FIling_Outcome.pdf

pdf

Download →
View document text
Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: July 23, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G, Bandra-Kurla Dalal Street, Mumbai – 400 001 Complex, Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Symbol: SOLARA, SOLARAPP1 Dear Sir/Madam, Sub: Outcome of Board Meeting held on July 23, 2026 and submission of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Board of Directors of the Company at their meeting held today i.e. July 23, 2026, have considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, together with the Limited Review Report issued by M/s. Deloitte Haskins & Sells, Chartered Accounts, Statutory Auditor of the Company. A copy of the Unaudited Financial Results along with the Limited Review Report has been enclosed herewith. Please note that the aforesaid unaudited Financial Results will also be available on the Company's website at https://solara.co.in/investor-relations/financial-information. The Board Meeting commenced at 12:00 P.M and concluded at 01:05 P.M. This is for your information and records. Thanking you, Yours faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer Membership No.: A57415 Encl.: As above Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 / Tel: +91-22- 2087 0033